Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06084780 · ClinicalTrials.gov registry record · Phase 2
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT06084780 is a Phase 2 study that has not yet begun recruiting, run by Case Comprehensive Cancer Center. The registered enrollment target is 20 participants.
The verdict
NCT06084780, a Phase 2 study, has not yet begun recruiting, sponsored by Case Comprehensive Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.
Interventions
- DRUG Sirolimus
- DRUG Alemtuzumab
- DRUG Tacrolimus
- PROCEDURE Intestinal, Multivisceral or Modified Multivisceral Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-08 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06084780
The ClinicalTrials.gov registry entry for NCT06084780 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sirolimus is the first listed.
NCT06084780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06084780 about?
NCT06084780 is a clinical study titled "Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)". The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed...
What is the current status of trial NCT06084780?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-08. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT06084780?
The interventions under investigation include: Sirolimus (DRUG), Alemtuzumab (DRUG), Tacrolimus (DRUG), Intestinal, Multivisceral or Modified Multivisceral Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT06084780?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.